DONALD R. KORST, M.D., F.A.C.P.; EUGENE P. FRENKEL, M.D.; JOHN C. NIXON, M.D.
Multiple myeloma, a neoplasm of plasma cell origin represents a difficult therapeutic problem. Preliminary clinical trials with a new alkylating agent cyclophosphamide1 (1) suggested that palliative responses in human multiple myeloma could be obtained. Investigations of myeloma have been limited by the lack of a suitable animal prototype; however, in 1957, Potter, Fahey, and Pilgrim (2) observed a plasma cell tumor in the iliocecum of C3H mice and successfully transferred the tumor subcutaneously through many generations. The tumor in mice produces bone marrow, liver, and spleen plasma cell invasion. Changes in the serum proteins are similar to the human disease.
KORST DR, FRENKEL EP, NIXON JC. Multiple Myeloma: Studies of Mouse Plasma Cell Tumor and Human Myeloma Responsiveness to Cyclophosphamide (Cytoxan). Ann Intern Med. ;60:217–230. doi: 10.7326/0003-4819-60-2-217
Download citation file:
Published: Ann Intern Med. 1964;60(2_Part_1):217-230.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use